Vertex Pharmaceuticals (1VRTX) Stock Statistics & Valuation Metrics
Total Valuation
Vertex Pharmaceuticals has a market cap or net worth of EUR 126.41B. The enterprise value is EUR 120.88B.
- Market Cap
- EUR 126.41B
- Enterprise Value
- EUR 120.88B
Share Statistics
Vertex Pharmaceuticals has 253,460,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 253,460,920
- Owned by Insiders
- 0.22%
- Owned by Institutions
- 3.03%
Financial Efficiency
Vertex Pharmaceuticals’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 18.12%.
- Return on Equity (ROE)
- 0.21
- Return on Assets (ROA)
- 0.15
- Return on Invested Capital (ROIC)
- 18.12%
- Return on Capital Employed (ROCE)
- 0.21
- Revenue Per Employee
- 1.89M
- Profits Per Employee
- 617.69K
- Employee Count
- 6,400
- Asset Turnover
- 0.46
- Inventory Turnover
- 1.07
Valuation Ratios
The current PE Ratio of Vertex Pharmaceuticals is 32.27. Vertex Pharmaceuticals’s PEG ratio is 1.43.
- PE Ratio
- 32.27
- PS Ratio
- 11.22
- PB Ratio
- 7.01
- Price to FCF
- 37.32
- Price to Operating Cash Flow
- 33.05
- PEG Ratio
- 1.43
Income Statement
In the last 12 months, Vertex Pharmaceuticals had revenue of 12.07B and earned 3.95B in profits. Earnings per share was 15.46.
- Revenue
- 12.07B
- Gross Profit
- 10.27B
- Operating Income
- 4.76B
- Pretax Income
- 4.64B
- Net Income
- 3.95B
- EBITDA
- 4.87B
- Earnings Per Share (EPS)
- 15.46
Cash Flow
In the last 12 months, operating cash flow was 4.29B and capital expenditures -496.80M, giving a free cash flow of 3.80B billion.
- Operating Cash Flow
- 4.29B
- Free Cash Flow
- 3.80B
- Free Cash Flow per Share
- 14.95
Dividends & Yields
Vertex Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.68%
- Earnings Yield
- 3.10%
Stock Price Statistics
- Beta
- 0.06
- 52-Week Price Change
- 37.53%
- 50-Day Moving Average
- 458.90
- 200-Day Moving Average
- 415.34
- Relative Strength Index (RSI)
- 68.47
- Average Volume (3m)
- 11
Important Dates
Vertex Pharmaceuticals upcoming earnings date is Nov 02, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 03, 2026
- Next Earnings Date
- Nov 02, 2026
- Ex-Dividend Date
- ―
Financial Position
Vertex Pharmaceuticals as a current ratio of 2.90, with Debt / Equity ratio of 20.80%
- Current Ratio
- 2.90
- Quick Ratio
- 2.46
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.25
- Interest Coverage Ratio
- 357.95
Taxes
In the past 12 months, Vertex Pharmaceuticals has paid 690.00M in taxes.
- Income Tax
- 690.00M
- Effective Tax Rate
- 0.15
Enterprise Valuation
Vertex Pharmaceuticals EV to EBITDA ratio is 24.98, with an EV/FCF ratio of 36.22.
- EV to Sales
- 10.89
- EV to EBITDA
- 24.98
- EV to Free Cash Flow
- 36.22
- EV to Operating Cash Flow
- 32.03
Balance Sheet
Vertex Pharmaceuticals has EUR 7.85B in cash and marketable securities with EUR 1.98B in debt, giving a net cash position of EUR 5.87B billion.
- Cash & Marketable Securities
- EUR 7.85B
- Total Debt
- EUR 1.98B
- Net Cash
- EUR 5.87B
- Net Cash Per Share
- EUR 23.18
- Tangible Book Value Per Share
- EUR 73.84
Margins
Gross margin is 86.04%, with operating margin of 38.59%, and net profit margin of 34.89%.
- Gross Margin
- 86.04%
- Operating Margin
- 38.59%
- Pretax Margin
- 41.78%
- Net Profit Margin
- 34.89%
- EBITDA Margin
- 43.60%
- EBIT Margin
- 41.84%
Analyst Forecast
The average price target for Vertex Pharmaceuticals is EUR 526.34, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 526.34
- Price Target Upside
- 4.91% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 25
- Revenue Growth Forecast
- 3.94%
- EPS Growth Forecast
- 14.68%
Scores
- Smart Score
- 9
- AI Score
- ―